Oral efficacy and bioavailability of a novel taxane

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2070-2074

  Polizzi, Donatella ^a   Pratesi, Graziella ^a   Monestiroli, Silvia ^a   Tortoreto, Monica ^a   Zunino, Franco ^a   Bombardelli, Ezio ^b   Riva, Antonella ^b   Morazzoni, Paolo ^b   Colombo, Tina ^c   D'Incalci, Maurizio ^c   Zucchetti, Massimo ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INDENA S P A   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESISTANCE; DRUG TOLERABILITY; INTESTINE ABSORPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 18844462763     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H-J., and Yang, C-P. H. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15: 55-61, 1993.
2. Rowinsky, E. K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med., 48: 353-374, 1997.
3. Casazza, A. M., and Fairchild, C. R. Paclitaxel (Taxol) mechanisms of resistance. In: W. N. Hait (ed.), Drug Resistance, pp. 149-171. Boston: Kluwer Academic Publishers, 1996.
4. Vanhoefer, U., Cao, S., Harstrick, A., Seeber, S., and Rustum, Y. M. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann. Oncol., 8: 1221-1228, 1997.
5. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
6. Fujita, H., Okamoto, M., Takao, A., Mase, H., and Kojima, H. Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level. Jpn. J. Cancer Chemother., 21: 653-658, 1994.
7. van Asperen, J., van Tellingen, O., van der Valk, M. A., Rozenhart, M. and Beijnen, J. H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res., 4: 2293-2297, 1998.
8. van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijnen, W. J. and Beijnen, J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer, 76: 1181-1183, 1997.
9. Appendino, G., Gariboldi, P., Gabetta, B., Pace, R., Bombardelli, E., and Viterbo, D. 14β-hydroxy-10-deacetyl-baccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.). J. Chem. Soc. Perkin Trans., 1: 2925-2929, 1992.
10. Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., De Vincenzo, R., Riva, A., Bombardelli, E., Ojima, I., Fattorossi, A., Benedetti Panici, P., and Mancuso, S. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetyl-baccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer, 72: 844-850, 1997.
11. Polizzi, D., Pratesi, G., Tortoreto, M., Supino, R., Riva, A., Bombardelli, E., and Zunino, F. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res., 59: 1036-1040, 1999.
12. Workman, P., Twentyman, P., Balkwill, F., Balmain, A., Chaplin, D., Double, J., Embleton, J., Newell, D., Raymond, R., Stables, J., Stephens, T., and Wallace, J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br. J. Cancer, 77: 1-10, 1998.
13. Colombo, T., Frapolli, R., Bombardelli, E., Morazzoni, P., Riva, A., D'Incalci, M., and Zucchetti, M. High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN 5109 in mouse plasma. J. Chromatogr. Biomed. Appl., 736: 135-141, 1999.
14. Sacchi-Landriano, G., Guardabasso, V., and Rocchetti, M. NL-FIT: a computer program for non-linear fitting. Comput. Programs Biomed., 16: 35-42, 1983.
15. van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P., and van Tellingen, O. Altered pharmacokinetics of vinblastine in mdr-1 a P-glycoprotein-deficient mice. J. Natl. Cancer Inst., 88: 994-999, 1996.
16. Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs, 9: 1-17, 1998.
17. Meerum Terwogt, J. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., and Schellens, J. H. M. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet, 552: 285, 1998.
18. Verweij, J., Clavel, M., and Chevalier, B. Paclitaxel (Taxol™) and docetaxel (Taxotere™): not simply two of a kind. Ann. Oncol., 5: 495-505, 1994.
19. Zhan, Z., Scala, S., Monks, A., Hose, C., Bates, S., and Fojo, T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother. Pharmacol., 40: 245-250, 1997.
20. Rose, W. C. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Natl. Cancer Inst. Monogr., 15: 47-53, 1993.
21. Eiseman, J. L., Eddington, N. D., Leslie, J., MacAuley, C., Sentz, D. L., Zuhowski, M., Kujawa, J. M., Young, D., and Egorin, M. J. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol., 34: 465-471, 1994.
22. DeMario, M. D., and Ratain, M. J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol., 16: 2557-2567, 1998.